Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[BREAST CANCER: FROM TARGETED THERAPY TO PRECISION MEDICINE].
Jerusalem G, Collignon J, Josse C, Schroeder H, Rorive A, Frères P, Lambert F, Koopmansch B, Poncin A, Bours V. Jerusalem G, et al. Among authors: josse c. Rev Med Liege. 2015 May-Jun;70(5-6):269-76. Rev Med Liege. 2015. PMID: 26285451 Free article. Review. French.
[Cancer therapy-induced cardiotoxicity].
Frères P, Poncin A, Moonen M, Josse C, Oury C, Bours V, Lancellotti P, Jerusalem G. Frères P, et al. Among authors: josse c. Rev Med Liege. 2016 Sep;71(9):382-387. Rev Med Liege. 2016. PMID: 28383833 Free article. Review. French.
Targeting ferroptosis resistance resensitizes metastatic HR+HER2- breast cancer cells to palbociclib-hormone therapy.
Pottier C, Montero-Ruiz L, Jehay R, Wery C, Baiwir D, Mazzucchelli G, Bekisz S, Thissen R, Josse C, Rorive A, Gofflot S, Dahmani A, Morisset L, Collignon J, Delvenne P, Marangoni E, Noël A, Jerusalem G, Sounni NE. Pottier C, et al. Among authors: josse c. Cancer Commun (Lond). 2025 Jan 13. doi: 10.1002/cac2.12646. Online ahead of print. Cancer Commun (Lond). 2025. PMID: 39801257 No abstract available.
Genetic evaluation of patients with multiple primary cancers.
Freire MV, Thissen R, Martin M, Fasquelle C, Helou L, Durkin K, Artesi M, Lumaka A, Leroi N, Segers K, Deberg M, Gatot JS, Habran L, Palmeira L, Josse C, Bours V. Freire MV, et al. Among authors: josse c. Oncol Lett. 2024 Oct 15;29(1):4. doi: 10.3892/ol.2024.14750. eCollection 2025 Jan. Oncol Lett. 2024. PMID: 39492936 Free PMC article.
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment.
Barthélémy P, Thibault C, Fléchon A, Gross-Goupil M, Voog E, Eymard JC, Abraham C, Chasseray M, Lorgis V, Hilgers W, Gobert A, Le Moulec S, Simon C, Nicolas E, Escande A, Pouessel D, Mouillet G, Josse C, Solbes MN, Lambert P, Loriot Y. Barthélémy P, et al. Among authors: josse c. Eur Urol Oncol. 2024 Oct 23:S2588-9311(24)00223-2. doi: 10.1016/j.euo.2024.09.014. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39448350 Free article.
Clinical outcomes for 2788 patients with transthyretin amyloidosis: Tafamidis meglumine early access program in France.
Lairez O, Réant P, Inamo J, Jeanneteau J, Bauer F, Habib G, Eicher JC, Lequeux B, Legallois D, Josse C, Hippocrate A, Bartoli M, Dubois M, Noirot Cosson C, Squara PA, Fievez S, Quinault A, Rudant J, Kharoubi M, Damy T. Lairez O, et al. Among authors: josse c. Arch Cardiovasc Dis. 2024 Oct 5:S1875-2136(24)00323-1. doi: 10.1016/j.acvd.2024.08.006. Online ahead of print. Arch Cardiovasc Dis. 2024. PMID: 39426850
69 results